Benefits of Sevelamer on Markers of Bone Turnover in Taiwanese Hemodialysis Patients

Journal of the Formosan Medical Association

Volumn 109, Issue 9, 2010, Pages 663-672

  Lin, Yu Feng ^a   Chen, Yung Ming ^a   Hung, Kuan Yu ^a   Chu, Tzong Shinn ^a   Kan, Wei Chih ^b   Huang, Chih Yuan ^c   Lin, Shuei Liong ^a   Kao, Tze Wah ^a   Huang, Jenq Wen ^a   Chiang, Wen Chih ^a   Yen, Chung Jen ^a   Tsai, Tun Jun ^a   Wu, Kwan Dun ^a   Wu, Ming Shiou ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

Author keywords

Bone turnover; Hemodialysis; Hypercalcemia; Hyperphosphatemia; Sevelamer hydrochloride

Indexed keywords

ALKALINE PHOSPHATASE; ALUMINUM SALT; BIOLOGICAL MARKER; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; COLECALCIFEROL; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER; VITAMIN D; ACETIC ACID DERIVATIVE; CALCIUM DERIVATIVE; CHELATING AGENT; POLYAMINE;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG CAPSULE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLATULENCE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOPARATHYROIDISM; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MELENA; NAUSEA; NERVOUS SYSTEM; NERVOUS SYSTEM ACTIVITY; PARATHYROID HORMONE BLOOD LEVEL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET FORMULATION; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ASIAN; BLOOD; BONE REMODELING; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DISORDERS OF MINERAL, ELECTROLYTE AND METAL METABOLISM; DRUG EFFECT; HYPERCALCEMIA; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY;

ACETATES; ADULT; AGED; ALKALINE PHOSPHATASE; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BONE REMODELING; CALCIUM COMPOUNDS; CALCIUM PHOSPHATES; CHELATING AGENTS; FEMALE; HUMANS; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; PHOSPHORUS; PHOSPHORUS METABOLISM DISORDERS; POLYAMINES; PROSPECTIVE STUDIES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 78049441696     PISSN: None     EISSN: 09296646     Source Type: Journal    
DOI: 10.1016/S0929-6646(10)60107-6     Document Type: Article

References (38)

1. Alfrey AC, LeGendre GR, Kaehny WD The dialysis encephalopathy syndrome. Possible aluminum intoxication. N Engl J Med 1976, 294:184-188.
2. Boyce BF, Fell GS, Elder HY, et al. Hypercalcaemic osteomalacia due to aluminium toxicity. Lancet 1982, 2:1009-1013.
3. Emmett M, Sirmon MD, Kirkpatrick WG, et al. Calcium acetate control of serum phosphate in HD patients. Am J Kidney Dis 1991, 17:544-550.
4. Slatopolsky E, Weerts C, Lopez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986, 315:157-161.
5. Blacher J, Guerin AP, Pannier B, et al. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001, 38:938-942.
6. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
7. London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003, 18:1731-1740.
8. Stevens LA, Djurdjev O, Cardew S, et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004, 15:770-779.
9. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident HD patients. Kidney Int 2007, 71:438-441.
10. Cannata Andia JB Adynamic bone and chronic renal failure: an overview. Am J Med Sci 2000, 320:81-84.
11. Hsu CH Are we mismanaging calcium and phosphate metabolism in renal failure?. Am J Kidney Dis 1997, 29:641-649.
12. Guh JY, Chen HC, Chuang HY, et al. Risk factors and risk for mortality of mild hypoparathyroidism in HD patients. Am J Kidney Dis 2002, 39:1245-1254.
13. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997, 29:66-71.
14. Chertow GM, Burke SK, Dillon MA, et al. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999, 14:2907-2914.
15. Goldberg DI, Dillon MA, Slatopolsky EA, et al. Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphate, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998, 13:2303-2310.
16. Hervas JG, Prados D, Cerezo S Treatment of hyperphos-phatemia with sevelamer hydrochloride in HD patients: a comparison with calcium acetate. Kidney Int Suppl 2003, S69-S72.
17. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in HD patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004, 65:1914-1926.
18. Slatopolsky EA, Burke SK, Dillon MA RenaGel, a nonab-sorbed calcium- and aluminum-free phosphate binder, lowers serum phosphate and parathyroid hormone. The RenaGel Study Group. Kidney Int 1999, 55:299-307.
19. Block GA, Hulbert-Shearon TE, Levin NW, et al. Association of serum phosphate and calcium × phosphate product with mortality risk in chronic HD patients: a national study. Am J Kidney Dis 1998, 31:607-617.
20. Block GA, Port FK Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000, 35:1226-1237.
21. Campean V, Neureiter D, Varga I, et al. Atherosclerosis and vascular calcification in chronic renal failure. Kidney Blood Press Res 2005, 28:280-289.
22. Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996, 27:394-401.
23. Goodman WG, London G, Amann K, et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004, 43:572-579.
24. Ribeiro S, Ramos A, Brandao A, et al. Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998, 13:2037-2040.
25. Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003, 14:159-168.
26. Fournier A, Said S, Ghazali A, et al. The clinical significance of adynamic bone disease in uremia. Adv Nephrol Necker Hosp 1997, 27:131-166.
27. Mucsi I, Hercz G Relative hypoparathyroidism and ady-namic bone disease. Am J Med Sci 1999, 317:405-409.
28. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int 1994, 46:855-861.
29. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004, 15:1943-1951.
30. Coco M, Rush H Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000, 36:1115-1121.
31. London GM, Marchais SJ, Guerin AP, et al. Association of bone activity, calcium load, aortic stiffness, and calcifications in ESRD. J Am Soc Nephrol 2008, 19:1827-1835.
32. Izumi M, Shirai K, Ito K, et al. Is 2.5 mEq/L the optimal calcium concentration of dialysate in the use of sevelamer hydrochloride? A study of the dialysate calcium concentration recommended by K/DOQI guidelines. Ther Apher Dial 2005, 9:24-31.
33. Iwata Y, Wada T, Yokoyama H, et al. Effect of sevelamer hydrochloride on markers of bone turnover in Japanese dialysis patients with low biointact PTH levels. Intern Med 2007, 46:447-452.
34. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003, 64:441-450.
35. Ferreira A, Frazao JM, Monier-Faugere MC, et al. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in HD patients. J Am Soc Nephrol 2008, 19:405-412.
36. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42:S1-201.
37. Couttenye MM, D'Haese PC, Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996, 11:1065-1072.
38. Urena P, Hruby M, Ferreira A, et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in HD patients. J Am Soc Nephrol 1996, 7:506-512.